The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab
Solange Peters, MD, PhD, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, presents the results of a subgroup analysis of PEARLS/KEYNOTE-091 (NCT02504372) which demonstrated an improved disease-free survival in patients treated with pembrolizumab compared with placebo. Disease-free survival in the PD-L1 tumor proportion score (TPS) less than 50% population was not significant, which was likely due to placebo overperformance and a smaller population size. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
